Understanding Premature Ejaculation Medications

Psychological contributors may include anxiety, stress, or relationship issues, while physical factors can range from hormonal imbalances to certain neurological conditions.

There are simple ways to treat premature ejaculation and medical intervention can provide individuals with tailored strategies that help solve the issue. Treatment for premature ejaculation often involves a combination of techniques. Behavioural strategies like the stop-start or squeeze techniques can be helpful. Medications such as selective serotonin reuptake inhibitors (SSRIs) or topical anaesthetics may be prescribed. Counselling or therapy can also be beneficial when psychological factors are involved. Specialists in medicine, nutrition, performance, and diagnostics. BSc (Hons) MBBS MRCGP AFHEA MA (Hons) AFMCP I occasionally experienced premature ejaculation during sex. Not every time, but enough that it became something that was weighing on my mind whenever I got intimate with a girl. My life is so much better now that it seems silly to have wasted so much time not being satisfied. The service is accessible and easily takes away the embarrassment factor. Answer a few simple questions to get the treatment you need. Hossein Sadeghi-Nejad, MD, FACS, and Richard Watson, MD, FACS A B S T R A C TIntroduction. Premature ejaculation (PE) is the most common form of male sexual dysfunction. Until very recently, scientific investigation of PE has been hampered by a lack of standardized definitions and objective, validated questionnaires.

Small numbers of randomized controlled studies evaluating various treatment options have also added to the challenges facing the clinicians who manage PE. This article provides a summary of some of the more relevant the peer-reviewed literature pertaining to the medical therapy of premature ejaculation. A retrospective review of peer reviewed publications relevant to the field of premature ejaculation and related medical therapies. Review of safety and efficacy of various medical therapies for premature ejaculation. Selective serotonin release inhibitors have been the most promising agents to date.

Analgesic, Opioid

Small numbers of randomized controlled studies evaluating various treatment options have also added to the challenges facing the clinicians who manage PE. This article provides a summary of some of the more relevant the peer-reviewed literature pertaining to the medical therapy of premature ejaculation. A retrospective review of peer reviewed publications relevant to the field of premature ejaculation and related medical therapies. Review of safety and efficacy of various medical therapies for premature ejaculation. Selective serotonin release inhibitors have been the most promising agents to date.

Transcutaneous posterior tibial nerve stimulation (TPTNS)

The on-demand “PRN” use of these agents is more convenient, gel erectile dysfunction but its efficacy is less well established. Chronic use of this class of medications has been associated with minor, but bothersome side effects. More recently, concern over the risk of an increased suicide rate in young men upon initiation of SSRIs has dampened enthusiasm. Recent experience with the use of Tramadol raises the hope that this might prove to be an agent as effective as SSRIs with less worrisome risk of side-effects. New trials on novel formulations of topical solutions are currently underway in the United States.

Squeeze technique

Interest in medical therapy for PE is rapidly increasing and reflected in a disproportionate number of publications in this field in the past few years. Clinical research in this field is hampered by the complexity, variability among different men and cultures, and subjectivity of PE. Reliable, appropriately controlled and assessed studies are generally lacking and carefully devised, methodically conducted research is much needed. Sadeghi-Nejad H, and Watson R. Premature ejaculation: Current medical treatment and new directions. The on-demand “PRN” use of these agents is more convenient, gel erectile dysfunction but its efficacy is less well established. Chronic use of this class of medications has been associated with minor, but bothersome side effects. More recently, concern over the risk of an increased suicide rate in young men upon initiation of SSRIs has dampened enthusiasm. Recent experience with the use of Tramadol raises the hope that this might prove to be an agent as effective as SSRIs with less worrisome risk of side-effects. New trials on novel formulations of topical solutions are currently underway in the United States. Interest in medical therapy for PE is rapidly increasing and reflected in a disproportionate number of publications in this field in the past few years. Clinical research in this field is hampered by the complexity, variability among different men and cultures, and subjectivity of PE.

Reliable, appropriately controlled and assessed studies are generally lacking and carefully devised, methodically conducted research is much needed. Sadeghi-Nejad H, and Watson R.

Risk factors

Nathan [7] analyzed the findings of 22 general population sex surveys, and estimated the prevalence of PE to be 35%. Most estimates from other general population prevalence studies fall between 22% and 38%, with ranges from 4% to 39% [8–10]. The wide variability in the reported ranges is mirrored in the variability and lack of standardized definitions for PE. A number of studies have raised the point that in spite of the high prevalence rates, PE is the disorder for which patients are least likely to seek professional assistance, raising the distinct possibility that the problem may be more prevalent than currently estimated [8,10]. More recently, the PE Prevalence and Attitudes (PEPA) internetbased survey of 12,133 men aged 18–70 in the United States, Germany, and Italy reported a prevalence of 22.7% [11].

Analysis of the Average Time to Ejaculate for Men

It is noteworthy that only 9% of the men in this survey had consulted a physician, and more than 90% reported little or no improvement after they sought treatment, leading to a general lack of satisfaction with the results. It has also been suggested that the prevalence of PE may vary between racial groups; one recent survey of 1,320 men found that PE was more prevalently admitted among Hispanic men, highlighting the importance of further investigation of ethnic and cultural variances in PE worldwide [12]. The recurrent emerging pattern appears to be that PE is a largely underdiagnosed condition. The etiology of PE has been traditionally divided between “psychogenic” and “biogenic” factors. Psychogenic causes include anxiety, an unpleasant introductory or early sexual experience, infrequent sexual intercourse, poor ejaculatory control techniques, and evolutionary as well as psychodynamic factors. Premature ejaculation: Current medical treatment and new directions. Interest in premature ejaculation (PE) has been increasing rapidly among all healthcare professionals.

A recent Medline search (January 2008) for articles related to PE, from 1949 to the present, uncovered a total of 589 references of which 160 articles (27%) had been published within the past 2 years. Much of this recent surge in interest has focused on new and promising medical relief for men who are troubled by this vexing condition. This review, while recognizing the critical importance of an integrated approach to the evaluation and management of PE—coordinating participation on the part of urologists, mental health professionals, endocrinologists, primary care physicians, and other interested healthcare professionals—is directed primarily at providing an update on recent developments in the medical treatment of PE. The definition of PE is still evolving, but the classic triad involved in the definition includes (i) short intravaginal ejaculatory latency time (IELT), (ii) lack of control, and (iii) sexual dissatisfaction [1]. The World Health Organization (WHO) 1994 International Classification of Diseases defines PE as “an inability to delay ejaculation sufficiently to enjoy lovemaking, manifest as either of the following: occurrence of ejaculation before or very soon after the beginning of intercourse (if a time limit is required: before or within 15 seconds of the beginning of intercourse); occurrence of ejaculation in the absence of sufficient erection to make intercourse possible. The problem is not the result of prolonged absence from sexual activity” [1].

• Topical anesthetic creams temporarily desensitize the penis to delay ejaculation.
• SSRI medications like paroxetine are prescribed off-label for premature ejaculation.
• Dapoxetine is a short-acting SSRI specifically approved for PE treatment.
• Tramadol, an opioid, can help delay ejaculation but carries dependency risks.
• Topical sprays offer quick, localized numbing effects to control ejaculation timing.
• PDE5 inhibitors like sildenafil may improve performance in men with PE and ED.
• Behavioral therapies include the stop-start and squeeze techniques to extend duration.
• Kegel exercises strengthen pelvic muscles, potentially delaying ejaculation.
• Counseling and sex therapy can address psychological causes of PE.
• Combining medication with behavioral techniques enhances treatment effectiveness.
• Herbal supplements lack robust clinical evidence but are used by some for PE.
• Consultation with a healthcare provider is essential to tailor appropriate therapy.

Furthermore, the WHO definition excludes men whose PE is predominately attributed to (i) alcohol, substance abuse, and/or medications; (ii) a sexual context that has led to very high levels of arousal because of the novelty of partner or situation; and (iii) a low frequency of sexual activity [1].

Additional info

Interest in premature ejaculation (PE) has been increasing rapidly among all healthcare professionals. A recent Medline search (January 2008) for articles related to PE, from 1949 to the present, uncovered a total of 589 references of which 160 articles (27%) had been published within the past 2 years. Much of this recent surge in interest has focused on new and promising medical relief for men who are troubled by this vexing condition. This review, while recognizing the critical importance of an integrated approach to the evaluation and management of PE—coordinating participation on the part of urologists, mental health professionals, endocrinologists, primary care physicians, and other interested healthcare professionals—is directed primarily at providing an update on recent developments in the medical treatment of PE. The definition of PE is still evolving, but the classic triad involved in the definition includes (i) short intravaginal ejaculatory latency time (IELT), (ii) lack of control, and (iii) sexual dissatisfaction [1].

Using thicker condoms

The World Health Organization (WHO) 1994 International Classification of Diseases defines PE as “an inability to delay ejaculation sufficiently to enjoy lovemaking, manifest as either of the following: occurrence of ejaculation before or very soon after the beginning of intercourse (if a time limit is required: before or within 15 seconds of the beginning of intercourse); occurrence of ejaculation in the absence of sufficient erection to make intercourse possible. The problem is not the result of prolonged absence from sexual activity” [1]. Furthermore, the WHO definition excludes men whose PE is predominately attributed to (i) alcohol, substance abuse, and/or medications; (ii) a sexual context that has led to very high levels of arousal because of the novelty of partner or situation; and (iii) a low frequency of sexual activity [1]. Others have based their diagnosis on the number of penile thrusts occurring before ejaculation, considering less than 8–15 thrusts as the criterion for PE [2,3]. In 2007, responding to the variability of worldwide definitions and the need for a universal standard, the International Society for Sexual Medicine (ISSM) established an ad hoc committee consisting of 21 internationally recognized experts, to establish a new definition of PE.

Sertraline (Zoloft®) for PE

This latest ISSM definition, based on the recommendations of the most active and respected clinical and basic science experts in the field, characterized PE as follows: “Premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy” [4]. Based on this new definition, some investigators may question the conclusions of previous studies with potentially inadequate patient selection definitions. Other related definitions include primary or lifelong PE—presence of the problem from the onset of initial sexual activity; acquired or late onset PE—indicates that the problem has developed after an initial time of unimpaired ejaculatory function; and situational (vs. global) PE—indicates PE that is limited to specific partner or situation, while the patient enjoys satisfactory intercourse in other contexts [5]. The National Health and Social Life Survey, a probability sample study of sexual behavior in men and women aged 18–59 years, reported a prevalence of fildena tablet 21% among men in the United States [6]. Others have based their diagnosis on the number of penile thrusts occurring before ejaculation, considering less than 8–15 thrusts as the criterion for PE [2,3]. In 2007, responding to the variability of worldwide definitions and the need for a universal standard, the International Society for Sexual Medicine (ISSM) established an ad hoc committee consisting of 21 internationally recognized experts, to establish a new definition of PE.

• Dapoxetine used before sex provides quick relief from PE.
• Topical anesthetic applications should be tailored to individual needs.
• SSRIs may cause delayed orgasm or decreased sexual desire.
• Tramadol is an alternative but carries substantial risks.
• Training with behavioral techniques can lead to lasting improvements.
• Fatigue and stress reduction support sexual performance.
• Pelvic floor strengthening is a natural method to control ejaculation.
• Psychological support addresses underlying emotional issues.
• Mechanical aids are an option for some men.
• Combining medications with psychotherapy enhances efficacy.
• Avoid self-medicating without professional advice.
• Consistent follow-up optimizes long-term management.

This latest ISSM definition, based on the recommendations of the most active and respected clinical and basic science experts in the field, characterized PE as follows: “Premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy” [4]. Based on this new definition, some investigators may question the conclusions of previous studies with potentially inadequate patient selection definitions. Other related definitions include primary or lifelong PE—presence of the problem from the onset of initial sexual activity; acquired or late onset PE—indicates that the problem has developed after an initial time of unimpaired ejaculatory function; and situational (vs.

Does Viagra help premature ejaculation?

Decreasing sensory perception in the penis has been the goal of most topical agents aimed at treating PE. As a general rule, reliable controlled studies have been lacking in this area. Penile biothesiometry studies have shown that patients with PE have increased penile sensitivity as shown by consistently decreased vibratory threshold that is not age dependent [24,25]. Lidocaine- or prilocaine-based sprays, creams, or gels, as well as eutectic (i.e., melts easily) mixtures, have shown promise [26,27]. Their application offers a rapid onset of effect, with relatively mild numbness. global) PE—indicates PE that is limited to specific partner or situation, while the patient enjoys satisfactory intercourse in other contexts [5].

• Dapoxetine's side effects can include nausea, headache, and dizziness.
• Topical anesthetics include lidocaine and prilocaine-based creams or sprays.
• SSRIs like fluoxetine, sertraline, may also be used off-label for PE.
• Opioid medications require careful medical oversight due to dependency potential.
• Behavioral approaches are first-line treatment for many men with PE.
• Regular exercise can improve overall sexual function and control.
• Some innovations include vibration devices to delay ejaculation temporarily.
• Medical tests may be recommended to exclude underlying causes.
• Education about sexual response stages can improve control strategies.
• Sex therapy often involves both partners to address relational issues.
• Medications may take several weeks to show maximum benefit.
• Lifestyle modifications, like reducing alcohol, can also help manage PE.

The National Health and Social Life Survey, a probability sample study of sexual behavior in men and women aged 18–59 years, reported a prevalence of fildena tablet 21% among men in the United States [6]. Nathan [7] analyzed the findings of 22 general population sex surveys, and estimated the prevalence of PE to be 35%. Most estimates from other general population prevalence studies fall between 22% and 38%, with ranges from 4% to 39% [8–10]. The wide variability in the reported ranges is mirrored in the variability and lack of standardized definitions for PE.

• Dapoxetine is specifically designed for on-demand use in PE.
• Topical anesthetics require minimal use to avoid excessive numbness.
• SSRIs impact neurotransmitters involved in ejaculation control.
• Tramadol's side effects limit its routine use for PE.
• Non-drug approaches include psychological counseling and exercises.
• Pelvic strengthening exercises aid in delay of ejaculation.
• Partner education enhances understanding and support.
• Managing stress and anxiety can significantly improve PE.
• Some therapies combine medication with sex therapy sessions.
• Medical evaluation is essential before initiating treatment.
• Lifestyle factors like smoking can influence sexual performance.
• Patient adherence to treatment plans improves outcomes.

A number of studies have raised the point that in spite of the high prevalence rates, PE is the disorder for which patients are least likely to seek professional assistance, raising the distinct possibility that the problem may be more prevalent than currently estimated [8,10]. More recently, the PE Prevalence and Attitudes (PEPA) internetbased survey of 12,133 men aged 18–70 in the United States, Germany, and Italy reported a prevalence of 22.7% [11].

Side effects of premature ejaculation pills

Urologic causes, including chronic prostatitis, have also been implicated [14]. Early animal studies revealed that nonselective agonists of the 5-HT2C receptors delay ejaculation, but selective 5-HT2A agonists do not have a similar effect, and selective 5-HT1A agonists cause a shorter ejaculatory latency compared with 5-HT2C agonists [15,16]. hypothesized that PE may be secondary to relative hyposensitivity of the 5-HT2C and/or 5-HT1A hypersensitivity [17]. The effect of postsynaptic 5-HT receptor activation on delayed ejaculation was later confirmed by using different selective serotonin reuptake inhibitors (SSRIs) [18–22]. The possible influence of genetic causes was investigated in a survey of 1,196 men in Finland that suggested the presence of a familial or genetic influence in 28% of men [23]. It is noteworthy that only 9% of the men in this survey had consulted a physician, and more than 90% reported little or no improvement after they sought treatment, leading to a general lack of satisfaction with the results. It has also been suggested that the prevalence of PE may vary between racial groups; one recent survey of 1,320 men found that PE was more prevalently admitted among Hispanic men, highlighting the importance of further investigation of ethnic and cultural variances in PE worldwide [12]. The recurrent emerging pattern appears to be that PE is a largely underdiagnosed condition. The etiology of PE has been traditionally divided between “psychogenic” and “biogenic” factors. Psychogenic causes include anxiety, an unpleasant introductory or early sexual experience, infrequent sexual intercourse, poor ejaculatory control techniques, and evolutionary as well as psychodynamic factors. Urologic causes, including chronic prostatitis, have also been implicated [14]. Early animal studies revealed that nonselective agonists of the 5-HT2C receptors delay ejaculation, but selective 5-HT2A agonists do not have a similar effect, and selective 5-HT1A agonists cause a shorter ejaculatory latency compared with 5-HT2C agonists [15,16]. hypothesized that PE may be secondary to relative hyposensitivity of the 5-HT2C and/or 5-HT1A hypersensitivity [17]. The effect of postsynaptic 5-HT receptor activation on delayed ejaculation was later confirmed by using different selective serotonin reuptake inhibitors (SSRIs) [18–22]. The possible influence of genetic causes was investigated in a survey of 1,196 men in Finland that suggested the presence of a familial or genetic influence in 28% of men [23]. Decreasing sensory perception in the penis has been the goal of most topical agents aimed at treating PE. As a general rule, reliable controlled studies have been lacking in this area. Penile biothesiometry studies have shown that patients with PE have increased penile sensitivity as shown by consistently decreased vibratory threshold that is not age dependent [24,25]. Lidocaine- or prilocaine-based sprays, creams, or gels, as well as eutectic (i.e., melts easily) mixtures, have shown promise [26,27].

Selective Serotonin Reuptake Inhibitors

Psychological contributors may include anxiety, stress, or relationship issues, while physical factors can range from hormonal imbalances to certain neurological conditions. There are simple ways to treat premature ejaculation and medical intervention can provide individuals with tailored strategies that help solve the issue. Treatment for premature ejaculation often involves a combination of techniques. Behavioural strategies like the stop-start or squeeze techniques can be helpful. Medications such as selective serotonin reuptake inhibitors (SSRIs) or topical anaesthetics may be prescribed.

Lidocaine (4%) Cream for PE

Counselling or therapy can also be beneficial when psychological factors are involved. Specialists in medicine, nutrition, performance, and diagnostics. BSc (Hons) MBBS MRCGP AFHEA MA (Hons) AFMCP I occasionally experienced premature ejaculation during sex. Not every time, but enough that it became something that was weighing on my mind whenever I got intimate with a girl. My life is so much better now that it seems silly to have wasted so much time not being satisfied.

Sex therapy

The service is accessible and easily takes away the embarrassment factor. Answer a few simple questions to get the treatment you need. Hossein Sadeghi-Nejad, MD, FACS, and Richard Watson, MD, FACS A B S T R A C TIntroduction. Premature ejaculation (PE) is the most common form of male sexual dysfunction. Until very recently, scientific investigation of PE has been hampered by a lack of standardized definitions and objective, validated questionnaires. Their application offers a rapid onset of effect, with relatively mild numbness.